Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  G1 Therapeutics Inc    GTHX

G1 THERAPEUTICS INC

(GTHX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

G1 Therapeutics to Report First Quarter Financial Results on May 9, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 07:01am EDT

RESEARCH TRIANGLE PARK, N.C., May 02, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to report financial results for the first quarter of 2019 on Thursday, May 9, 2019 at 4:30 p.m. ET.

The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 7988598. A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib and lerociclib are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Head of Investor Relations/Public Relations
919-907-1944
jmacdonald@g1therapeutics.com

G1 Therapeutics.jpg


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on G1 THERAPEUTICS INC
06/19G1 THERAPEUTICS : Announces Updated Results from Phase 2 Trial of Trilaciclib in..
AQ
06/18G1 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
06/18G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib i..
GL
06/14G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilacicli..
GL
06/14G1 THERAPEUTICS : Announces Updates to Board of Directors
AQ
06/13G1 THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of..
AQ
06/13G1 Therapeutics Announces Updates to Board of Directors
GL
06/12G1 THERAPEUTICS : to Present at Raymond James Life Sciences and MedTech Conferen..
AQ
06/11G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Confere..
GL
06/03G1 THERAPEUTICS : Presents Additional Phase 2 Data on Trilaciclib in Small Cell ..
AQ
More news
Financials ($)
Sales 2019 -
EBIT 2019 -116 M
Net income 2019 -111 M
Finance 2019 396 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 0
EV / Sales 2020 0
Capitalization 984 M
Chart G1 THERAPEUTICS INC
Duration : Period :
G1 Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends G1 THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 69,0 $
Spread / Average Target 163%
EPS Revisions
Managers
NameTitle
Mark A. Velleca President, Chief Executive Officer & Director
Seth A. Rudnick Chairman
Barclay A. Phillips CFO & Senior VP-Corporate Development
Jay C. Strum Chief Scientific Officer
Rajesh K. Malik Chief Medical Officer & Senior Vice President-R&D
Sector and Competitors
1st jan.Capitalization (M$)
G1 THERAPEUTICS INC37.13%747
GILEAD SCIENCES9.13%80 909
VERTEX PHARMACEUTICALS7.38%42 680
REGENERON PHARMACEUTICALS-16.78%32 744
GENMAB14.52%10 857
SAREPTA THERAPEUTICS INC23.17%8 523